Contact us 24/7

Daclatasvir and BMS-986094

Attention Hepatitis C Trial Patients

CRITICAL INFORMATION FOR HEP C TRIAL PATIENTS: Thomas J. Henry has uncovered information that could drastically affect your health. We are currently representing Hepatitis C clinical trial patients who sustained heart and kidney injuries and who are suffering from bone marrow suppression and other immune deficiency issues. Symptoms that begin as shortness of breath, heart palpitations, and swelling of the legs can progress to renal failure, heart attack, and death. You may not even know you were injured. Contact our officesimmediately for more information.

BRISTOL-MYERS SQUIBB HEPATITIS C TRIALS QUESTIONED

Thomas J. Henry is currently investigating reports of possible heart failure in patients involved in a recent clinical trial for the Bristol-Myers Squibb Hepatitis C drugs Daclatasvir and BMS-986094 (formerly known as INX-189). Phase II of the clinical trial was halted on August 1, 2012 after reports that at least one person suffered sudden heart failure during the study.

Bristol-Myers Squibb discontinued development of BMS-986094 following the report of the heart failure and nine hospitalizations, some due to heart and kidney toxicity, from the drug.

HEPATITIS C DRUGS TESTED IN CLINICAL TRIAL

  • Daclatasvir is an experimental NS5a inhibitor, used alone or in combination with other drugs in clinical trials for treatment of Hepatitis C.
  • BMS-986094 is a nucleotide polymerase inhibitor, studied in combination with Daclatasvir and other drugs for Hepatitis C treatment.
  • BMS-986094 has been hailed as one of the most promising future treatments for Hepatitis C.
  • Due to the suspension of the BMS-986094 study, similar compounds by Idenix – IDX184 and IDX19368 – have also been placed on clinical hold.
  • A retrospective review of MS-986094 found that roughly 40 percent of patients treated with BMS-986094 developed some kind of cardiac dysfunction.
INJURIES THAT MAY BE RELATED TO CLINICAL TRIALS
  • Fatigue
  • Nausea/vomiting
  • Shortness of breath
  • Decreased urine production
  • Kidney damage
  • Renal Failure
  • Swelling of the legs
  • Feelings of anxiety
  • Bone marrow suppression
  • Inability to make blood cells, immune cells, or platelets
  • Heart palpitations
  • Chest pain
  • Abnormal heart rhythm
  • Valve inflammation
  • Cardiomyopathy
  • Heart damage
  • Heart attack
  • Heart failure
  • Death
CLINICAL TRIALS HELD THROUGHOUT UNITED STATES

The clinical trials for Bristol-Myers Squibb may have taken place all over the country. Cities that may have held clinical trials include:

  • San Antonio, Texas
  • Arlington, Texas
  • Austin, Texas
  • Houston, Texas
  • Dallas, Texas
  • Hoover, Alabama
  • Montgomery, Alabama
  • Anaheim, California
  • La Jolla, California
  • San Diego, California
  • San Francisco, California
  • Orlando, Florida
  • Atlanta, Georgia
  • Augusta, Georgia
  • New York, New York
  • Asheville, North Carolina
  • Tulsa, Oklahoma
  • Portland, Oregon
  • Fairfax, Virginia
  • Seattle, Washington
  • Newport News, Virginia
  • Seattle, Washington
SERIOUS RISKS MAY HAVE BEEN HIDDEN FROM HEP C TRIAL PARTICIPANTS

You may not have been informed about all the risks and long-term effects of participating in this trial. Ask yourself the following questions:

  • Did you understand all the trial enrollment paperwork you signed?
  • Were you confused by the consent forms?
  • Did you have lingering questions about side effects?
  • Did your doctor fail to explain all the possible outcomes of the trial?
  • Were you told you had a problem and then told something different by another doctor?
  • Were you referred to several doctors during your initial treatment and after the trial?

HAVE YOU BEEN INJURED?

If you’ve been injured, we can help. Contact us